EGFR inhibitors: Iressa, Tarceva, and Erbitux (gefitinib, erlotinib, and: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

30 March 2024

27 March 2024

  • curprev 21:1821:18, 27 March 2024‎ Lazy talk contribs‎ 5,883 bytes +5,883‎ Created page with " {{TreatmentInfo |drug_name=EGFR inhibitors: Iressa, Tarceva, and Erbitux (gefitinib, erlotinib, and |category=Other Chemotherapy and Cancer Drugs |book_text=cetuximab) These three drugs, which have FDA approval for several different types of cancer, have the common feature that they target a growth-signaling channel known as the epidermal growth factor. Overexpression or mutation of EGF receptors is involved in the growth many different kinds of cancer, including more..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=EGFR_inhibitors:_Iressa,_Tarceva,_and_Erbitux_(gefitinib,_erlotinib,_and"